CA2125293A1 - Traitement du cancer colorectal - Google Patents

Traitement du cancer colorectal

Info

Publication number
CA2125293A1
CA2125293A1 CA002125293A CA2125293A CA2125293A1 CA 2125293 A1 CA2125293 A1 CA 2125293A1 CA 002125293 A CA002125293 A CA 002125293A CA 2125293 A CA2125293 A CA 2125293A CA 2125293 A1 CA2125293 A1 CA 2125293A1
Authority
CA
Canada
Prior art keywords
course
day
therapy
hydroxy
repeated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002125293A
Other languages
English (en)
Inventor
Randall Keith Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2125293A1 publication Critical patent/CA2125293A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
CA002125293A 1991-12-10 1992-07-24 Traitement du cancer colorectal Abandoned CA2125293A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80457091A 1991-12-10 1991-12-10
US07/804,570 1991-12-10

Publications (1)

Publication Number Publication Date
CA2125293A1 true CA2125293A1 (fr) 1993-06-24

Family

ID=25189304

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002125293A Abandoned CA2125293A1 (fr) 1991-12-10 1992-07-24 Traitement du cancer colorectal

Country Status (7)

Country Link
EP (1) EP0661977A1 (fr)
JP (1) JPH07501818A (fr)
AU (1) AU2394392A (fr)
CA (1) CA2125293A1 (fr)
MX (1) MX9205766A (fr)
PT (1) PT100948A (fr)
WO (1) WO1993011770A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552154A (en) 1989-11-06 1996-09-03 The Stehlin Foundation For Cancer Research Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
DE69435084T2 (de) * 1993-01-15 2009-03-19 The Stehlin Foundation For Cancer Research, Houston Die Verwendung von wasserunlöslichem S-Camptothecin mit geschlossenem Lactonring für die Herstellung eines Medikamentes zur Behandlung von Darmkrebs
US6291425B1 (en) * 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
ES2371171B1 (es) * 2010-06-08 2012-11-16 Consejo Superior De Investigaciones Científicas (Csic) Derivados de camptotecina como agentes antitumorales.
CN102477042A (zh) * 2010-11-26 2012-05-30 复旦大学 10-羟基喜树碱衍生物及其制备方法和用途
CN102659800B (zh) * 2012-05-11 2014-09-03 中国药科大学 一类低氧激活抗肿瘤化合物及其用途
CN103113381B (zh) * 2013-02-26 2014-12-10 大连理工大学 系列水溶性羟基喜树碱环烷胺醇衍生物及其制法与用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004758A (en) * 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
JPH0641161B2 (ja) * 1988-02-17 1994-06-01 積水化成品工業株式会社 スチレン系樹脂発泡シートの製造方法及び加熱成形用スチレン系樹脂発泡シート
JPH0768403B2 (ja) * 1988-12-15 1995-07-26 東洋エンジニアリング株式会社 発泡体の製造方法
JP2756366B2 (ja) * 1990-11-27 1998-05-25 松下電工株式会社 疎水性エアロゲルの製造方法

Also Published As

Publication number Publication date
AU2394392A (en) 1993-07-19
MX9205766A (es) 1993-06-01
PT100948A (pt) 1994-01-31
WO1993011770A1 (fr) 1993-06-24
JPH07501818A (ja) 1995-02-23
EP0661977A1 (fr) 1995-07-12
EP0661977A4 (fr) 1994-10-20

Similar Documents

Publication Publication Date Title
CA2123321C (fr) Chimiotherapie d'association
WO2004043389B1 (fr) Procedes de traitement du cancer et procedes connexes
EP1171121A2 (fr) Compositions pharmaceutiques comprenant des inhibiteurs de dipeptidyl peptidase iv favorisant la croissance
Burke et al. Imidazole carboxamide therapy in advanced malignant melanoma
CA2125293A1 (fr) Traitement du cancer colorectal
US5674872A (en) Treatment of ovarian cancer
AU664172B2 (en) Treatment of esophageal cancer
CA2103707C (fr) Traitement des carcinomes pulmonaires autres que le cancer pulmonaire a petites cellules
EP0338679A2 (fr) Utilisation du facteur necrosant des tumeurs dans le traitement du cancer de la vessie
EP0572557B1 (fr) Utilisation de topotecan dans la preparation d'un medicament pour le traitement du cancer des ovaires
KR20030082544A (ko) 캄프토테신과 스틸벤 유도체를 포함하는 암 치료용 배합물
UA69423C2 (uk) Засіб для лікування пухлини печінки шляхом введення метоксиморфолінодоксорубіцину (mmdx) через печінкову артерію (варіанти)
CA2501610C (fr) Derives epothilone pour le traitement du myelome multiple
CA2501717C (fr) Utilisation de derives d'epothilone pour le traitement de l'hyperparathyroidie
Korfel et al. Phase-I tolerability study of 5-methyltetrahydrofolate in combination with a 4-hour infusion of 5-Fluorouracil in cancer-patients

Legal Events

Date Code Title Description
FZDE Dead